Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications


June 12, 2012
95 Pages - SKU: XGBR3937722
License type:
Table of Contents Search inside this report Related Reports Detailed Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
3 Translational Regenerative Medicine - Market Overview
3.1 Introduction and Background – What is Translational Regenerative Medicine?
3.1.1 Patent Landscape
3.1.2 Regenerative Therapy in Unregulated Settings
3.1.3 Currently Marketed Products – Overview
3.2 Potential Future Impact on the Pharmaceutical Landscape
3.2.1 Overcoming Shortfalls in Pharmaceuticals to Treat some Diseases
3.2.2 New Area for Pharmaceutical Companies to Enter through Licensing Agreements
3.2.3 Highly Priced Therapies
3.2.4 Emerging Economies are Embracing Regenerative Medicine
3.2.5 Academia/Small Biotech Collaborations
4 Regenerative Medicine - Stem Cell Therapy
4.1 Overview
4.2 Different Types of Stem Cells
4.2.1 Embryonic Stem Cells
4.2.2 Mesenchymal Stem Cells
4.2.3 Induced Pluripotent Stem Cells
4.2.4 Very Small Embryonic-Like Stem Cells
4.3 Manufacturing Stem Cells – Challenges of Achieving Large-Scale Consistency
4.4 Market Analysis
4.4.1 Market Prospects
4.4.2 Reimbursement
4.4.3 Service Industries around Stem Cell Therapy
4.5 Discontinued Molecules
4.6 Applications
4.7 Applications: Cardiovascular
4.7.1 Myocardial Infarction
4.7.2 Heart Failure
4.7.3 Congestive Heart Failure
4.7.4 Critical Limb Ischemia
4.8 Applications: Central Nervous System Disorders
4.8.1 Parkinson’s Disease
4.8.2 Multiple Sclerosis
4.8.3 Alzheimer’s Disease
4.8.4 Amyotrophic Lateral Sclerosis
4.8.5 Stroke
4.8.6 Spinal Cord Injury
4.9 Applications: Oncology
4.9.1 Haematological Malignancies
4.10 Applications: Gastrointestinal
4.10.1 Crohn’s Disease and Perianal Fistulas
4.11 Applications: Musculoskeletal
4.11.1 Spinal Fusion
4.12 Late-stage Pipeline Products Overview
4.12.1 Phase III
4.13 Marketed Products
4.13.1 Hearticellgram-AMI
4.13.2 Cartistem
4.13.3 Cupistem
4.14 Drivers/Barriers
4.14.1 Manufacturing Cells Faces Problems in Terms of Achieving Large-Scale Consistency
4.14.2 The Formation of Tumors from Stem Cells is an Ongoing Issue that Must be Overcome
4.14.3 Ethical Issues Delay Research
4.14.4 Stem Cell Tourism Decreases Confidence in Stem Cell Therapy and Overshadows Genuine Research
4.14.5 Many Stem Cell Therapies are Minimally Invasive
5 Regenerative Medicine - Gene Therapy
5.1 Overview
5.2 Gene Therapy Delivery Mechanisms
5.3 Market Analysis
5.4 Applications
5.4.1 Oncology
5.4.2 CNS
5.4.3 Cardiovascular
5.5 Currently Marketed Products
5.5.1 Gendicine
5.5.2 Oncorine
5.5.3 Rexin-G
5.6 Pipeline Prospects
5.6.1 Phase III and NDA Filing
5.7 Setbacks with Late-Stage Pipeline Products
5.7.1 Glybera
5.7.2 Cerepro
5.8 Drivers/Barriers
5.8.1 High Profile Deaths Reduce Confidence in the Field among Companies, Regulatory Authorities and Patients
5.8.2 Safety Issues with Use of Viral Vectors
5.8.3 Ensuring a Long-term Therapeutic Benefit from Gene Therapy is Difficult
5.8.4 Scientific Hurdles to Overcome are Still Numerous
5.8.5 Approvals in China have been Criticized as Being too Hasty
6 Regenerative Medicine - Tissue Engineering
6.1 Overview
6.2 Types of Scaffold
6.3 Market Analysis
6.4 Applications
6.4.1 Organ Transplantation
6.4.2 Wound Management
6.4.3 Orthopedics
6.4.4 Cardiovascular
6.5 Marketed Products
6.5.1 Apligraf
6.6 Drivers/Barriers
6.6.1 Drivers
6.6.2 Barriers
7 Translational Regenerative Medicine to 2018 - Geographical Landscape
7.1 The US
7.1.1 Regulatory Overview
7.1.2 Current Legislation and Regulatory Framework
7.1.3 Probable Future Developments
7.2 The EU
7.2.1 The UK
7.2.2 France
7.2.3 Germany
7.2.4 Italy
7.3 Japan
7.4 Other Economies
7.4.1 China
7.4.2 South Korea
7.4.3 Israel
7.4.4 Singapore
7.4.5 Australia
7.4.6 Canada
8 Translational Regenerative Medicine to 2018: Opportunities and Challenges
8.1 Opportunities
8.1.1 An Increasingly Elderly Population Increases the Number of Patients that Could Benefit from Regenerative Therapies
8.1.2 Regenerative Medicine Targets Diseases with High Unmet Need
8.1.3 There are Many Organizations Providing Funding, Including Private, Government and Public Bodies
8.1.4 High Treatment Costs
8.1.5 Many Countries have Permissive Laws Designed to Encourage Regenerative Medicine Innovation
8.2 Challenges
8.2.1 High Costs will Cause Problems with Reimbursement
8.2.2 There are High Risks to Investment
8.2.3 “One to Many” or “One to One” Approach to Regenerative Therapy?
8.2.4 European Court of Justice Ruled that Patents Cannot Apply to the Products of Research Involving the Destruction of Human Embryos
8.2.5 The Regulatory Landscape is Young and Requires Further Formalization
8.2.6 There are Still Many Scientific and Technical Hurdles to Overcome
8.2.7 Unregulated Use of Regenerative Medicine Harms the Research Landscape
9 Translational Regenerative Medicine to 2018 - Competitive Landscape
9.1 Companies Overview
9.2 Company Profiles
9.2.1 Ark Therapeutics
9.2.2 Organogenesis
9.2.3 Tengion
9.2.4 Advanced BioHealing
9.2.5 AMT
9.2.6 GSK
9.2.7 Epeius
9.2.8 Osiris
9.2.9 Cardio3
9.2.10 CorMatrix Cardiovascular
9.2.11 Aastrom
9.2.12 BioHeart
9.2.13 Cytori
9.2.14 Mesoblast
9.2.15 Geron
9.2.16 ReNeuron
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Sources
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.5 Therapeutic Landscape
10.5.1 Epidemiology-based Forecasting
10.5.2 Market Size by Geography
10.6 Geographical Landscape
10.7 Pipeline Analysis
10.8 Competitive Landscape
10.8.1 Expert Panel Validation
10.9 Contact Us
10.10 Disclaimer
10.11 Disclaimer
1.1 List of Tables
Table 1: Cystic Fibrosis Therapeutics Market, Global, Phase III Pipeline, 2011
Table 2: Organogenesis Products, 2011
1.2 List of Figures
Figure 1: Regenerative Medicine, Global, Main Branches, 2009
Figure 2: Stem Cell Therapy, Global, Types of Stem Cell, 2012
Figure 3: Stem Cell Therapy, Global, Historic Revenue, $m, 2005–2010
Figure 4: Stem Cell Therapy, Global, Pipeline by Therapy Area, 2011
Figure 5: Stem Cell Therapy, Global, Cardiovascular Pipeline by Phase, 2012
Figure 6: Stem Cell Therapy, Global, CNS Pipeline by Phase, 2012
Figure 7: Stem Cell Therapy, Global, Oncology Pipeline by Phase, 2012
Figure 8: Stem Cell Therapy, Global, Gastrointestinal Pipeline by Phase, 2012
Figure 9: Stem Cell Therapy, Global, Musculoskeletal Pipeline by Phase, 2012
Figure 10: Stem Cell Therapy, Global, Drivers and Barriers, 2012
Figure 11: Gene Therapy, Delivery Mechanisms Overview, 2012
Figure 12: Gene Therapy, Global, Pipeline by Therapy Area, 2012
Figure 13: Gene Therapy, Global, Oncology Pipeline by Phase, 2012
Figure 14: Gene Therapy, Global, CNS Pipeline by Phase, 2012
Figure 15: Gene Therapy, Global, Cardiovascular Pipeline by Phase, 2012
Figure 16: Gene Therapy, Global, Drivers and Barriers, 2012
Figure 17: Tissue Engineering, Scaffold Types, 2012
Figure 18: Tissue Engineering, Global, Drivers and Barriers, 2012
Figure 19: Translational Regenerative Medicine, Global, Drivers and Barriers, 2012
Figure 20: Ark Therapeutics, SWOT, 2011
Figure 21: Organogenesis, SWOT, 2011
Figure 22: Tengion, SWOT, 2011
Figure 23: Advanced Biohealing, SWOT, 2011
Figure 24: AMT, SWOT, 2011
Figure 25: GBI Research Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Oncology/Hematology Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!